In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MorphoSys divestment brings €53m to invest in pipeline

This article was originally published in Scrip

Executive Summary

With the sale of its research and diagnostic antibody business AbD Serotec, MorphoSys will gain €53 million in cash to invest in its therapeutic pipeline. The company is off-loading the non-core business, which analysts at Nomura Code note has "struggled to grow sales beyond the €20 million mark, which may have been related to the company's limited scale and share of voice in the research and diagnostic antibody market", to industry major Bio-Rad.

You may also be interested in...



Big Pharma’s Aging Antibodies Cling To Their Crowns

The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?

Novartis To Pay $9.7bn For The Medicines Company

Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Topics

Related Companies

UsernamePublicRestriction

Register

SC019789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel